Clinical trials need participants, are the rules about compensation helping or hurting?
Terry Gerton Your office recently put out a request for information on payments to clinical trial participants. That’s an interesting topic and one probably that most people don’t talk about very often, but what is it about what’s going on now that is of interest…
Terry Gerton Your office recently put out a request for information on payments to clinical trial participants. That’s an interesting topic and one probably that most people don’t talk about very often, but what is it about what’s going on now that is of.
Spencer Turnbull We issued this request for information or RFI because we want to improve our understanding of how clinical trials are providing remuneration to trial participants, and to learn whether the federal anti-kickback statute is viewed as a barrier to providing appropriate remunerations.
What Happened
And if I might, Terry, I know I’ve used at least three technical sounding terms, and I would love to briefly explain what each of them means for our listeners who might not be steeped in healthcare law. So you go with.
Terry Gerton is host of the Federal Drive and has been working in or with the federal government for more than 40 years.
And of course we’ll consider everything that we receive and are grateful for those submissions.
Spencer Turnbull Of course, I can’t speak for how our commenters approach the RFI, but based on our experience, RFIs usually generate candid useful information.
Key Details
Well, these are really at the heart of the RFI that we’re discussing. You might know that HHSOIG is at the forefront of America’s efforts to fight waste, fraud, and abuse in HHS programs, but you may not have heard of the.
Terry Gerton As industry folks might be responding to this, is there a tension between what they want to communicate to you so that the safe harbor rules get written effectively and what they.
So, depending on what we learn, potential next steps could include updated guidance, rulemaking or other efforts to modernize how fraud and abuse frameworks apply in clinical research.
We’re especially interested in areas where clarity, a new safe harbor, or a modification to existing regulations could support responsible research participation while maintaining strong protections against fraud and abuse.
Why It Matters
I might just call it the kickback statute for short, but this is one of HHSOIG’s most powerful tools to deter and prosecute fraud. The kickback statute is a criminal law and it prohibits the knowing and willful payment of remuneration, that’s.
Spencer Turnbull Well, I hope that commenters will provide real-world examples, data, and of course their perspectives that illustrate how payment practices are functioning today.
What kind of information would be most useful for you as you’re looking for evidence that supports one side or the other here?
What Reports Say
Coverage of the story so far points to:
Continued reporting by Federal News Network as more details emerge